Avisi
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1733 Woodside Rd Ste 310, Redwood City, ...Phone Number
(240) 439-8830Website
www.avisitech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Avisi
Avisi Technologies is a clinical-stage medical device company committed to advancing vision care through innovative ophthalmic solutions. The company's portfolio includes state-of-the-art treatments for glaucoma and other ocular conditions. These include its flagship VisiPlate® aqueous shunt, V-001 sustained intraocular drug-delivery platform, and the VisiPlate-S drainage device for treating mild to moderate glaucoma at the time of cataract surgery. Avisi has been recognized and supported by numerous organizations, including the National Science Foundation (NSF), the Glaucoma Research Foundation, SXSW, Johnson & Johnson JLABs, Medtech Innovator Accelerator, UCSF Rosenman Institute, and the University of Pennsylvania, among others. Avisi is funded by venture capital investors, angel investors, and scientific research grants.Explore more
Avisi Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Avisi your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Avisi
Avisi, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Avisi has recently received funding, and reach out quickly before it becomes old news!
Click to see if Avisi had a recent Job posting/layoffs
Check out if Avisi is spiking on competitors!
Product Launch: Get notified when Avisi launches new products
Earning: See what the market has to say on Avisi recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Avisi has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Avisi
Compare insights from companies similar to Avisi, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Avisi is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Avisi is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Avisi.
Avisi financials insights
Gather financial insights about Avisi, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series A
$10.7M
Avisi Tech Stack
A closer look at the technologies used by Avisi
See more technologies
Avisi News & Media
Avisi Technologies Announces First Patient Implanted with VisiPlate® Glaucoma Treatment Device in the SAPPHIRE Trial
The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sacramento Eye Consultants, in Sacramento, California. SAPPHIRE Trial is a prospective, multicenter, open-label clinical trial with 1-year follow up, evaluating safety and effectiveness of...Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate® Aqueous Shunt at AAO 2025
Almost half of patients medication free at 12 months. Vast majority of patients achieved significant IOP reduction on the same or fewer medications. Strong 12-month safety and efficacy results: no serious adverse events. REDWOOD CITY, Calif., Nov. 3, 2025 /PRNewswire/ -- Avisi...Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatment
Approved SAPPHIRE trial is a prospective, multicenter, open-label clinical trial with 1-year follow up, evaluating safety and effectiveness of VisiPlate® aqueous shunt in glaucoma patients. VisiPlate® shunt is uniquely designed: novel metamaterial, thinner than a human hair, aiming for...Avisi Technologies Presents Positive Six-Month Clinical Data for VisiPlate® Aqueous Shunt at the American Glaucoma Society
REDWOOD CITY, Calif., April 2, 2025 /PRNewswire/ -- Avisi Technologies, a clinical-stage ophthalmic device company, today announced encouraging six‐month interim results from the VITA trial evaluating its VisiPlate® device, an ultrathin, multichannel aqueous shunt in study subjects...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Avisi
Sign Up For FreeTo access detailed company insights
Avisi Technologies is a clinical-stage medical device company committed to advancing vision care through innovative ophthalmic solutions. The company's portfolio includes state-of-the-art treatments for glaucoma and other ocular conditions. These include its flagship VisiPlate® aqueous shunt, V-001 sustained intraocular drug-delivery platform, and... Read More
